ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,487.03
0.25%
US Tech 100
19,430.40
0.14%
다우존스 지수
38,834.86
0.15%
Bitcoin
65,552.35
0.63%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Phio Pharmaceuticals Corporation (PHIO)

  7. Phio Pharmaceuticals Corporation (PHIO) 뉴스

PHIO

Phio Pharmaceuticals (PHIO)

Phio Pharmaceuticals Corporation
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:PHIO
일자시간출처헤드라인심볼기업
2024/05/2906:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/2106:03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/2105:59Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1805:45Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1722:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1722:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1722:00GlobeNewswire Inc.Phio Pharmaceuticals Secures New InvestorNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1722:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1722:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1621:00GlobeNewswire Inc.Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1602:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation StudyNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1006:25GlobeNewswire Inc.Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1006:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/1006:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/0906:04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/0906:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/05/0906:00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/04/3020:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/04/2302:10GlobeNewswire Inc.Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/04/1620:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/04/1120:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/04/0320:30GlobeNewswire Inc.National Spotlight Features Phio’s Innovative RNAi Technology PlatformNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/04/0220:30GlobeNewswire Inc.Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/03/2120:30GlobeNewswire Inc.Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/03/1403:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/03/0700:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/03/0609:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/02/2109:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/02/0700:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PHIOPhio Pharmaceuticals Corporation
2024/01/3122:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
 검색 관련기사 보기:NASDAQ:PHIO

최근 히스토리

NYSE
DIS
Walt Disney
USOTC
BASFY
BASF (QX)
CCOM
SILVER
SILVER
COIN
BTCUSD
Bitcoin
NYSE
MCD
McDonalds
USOTC
RHHBY
Roche (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
CVX
Chevron
AMEX
XLF
Financial Select Sector
USOTC
ADDYY
Adidas (QX)
NASDAQ
MSFT
Microsoft
NYSE
MRK
Merck
NYSE
VZ
Verizon Communications
NYSE
AXP
American Express
NASDAQ
AMZN
Amazon.com
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유